Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Abstract Background The efficacy of olanzapine as an antiemetic agent in cancer chemotherapy has been demonstrated. However, few high-quality reports are available on the evaluation of olanzapine’s efficacy and safety at a low dose of 5 mg among patients treated with carboplatin regimens. Therefore,...

Full description

Bibliographic Details
Main Authors: Senri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, Hitoshi Kawazoe, Kazuki Tanaka, Yukiyoshi Fujita, Masakazu Abe, Hisao Imai, Masato Karayama, Yoh Hayasaki, Chiemi Hirose, Takafumi Suda, Kazuto Nakamura, Akio Suzuki, Yasushi Ohno, Ken-ichirou Morishige, Naoki Inui
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Antiemetics
Carboplatin
Nausea
Olanzapine
Vomiting
Online Access:https://doi.org/10.1186/s12885-021-08572-3

Internet

https://doi.org/10.1186/s12885-021-08572-3

Similar Items